171 related articles for article (PubMed ID: 16217747)
1. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations.
Györffy B; Surowiak P; Kiesslich O; Denkert C; Schäfer R; Dietel M; Lage H
Int J Cancer; 2006 Apr; 118(7):1699-712. PubMed ID: 16217747
[TBL] [Abstract][Full Text] [Related]
2. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
3. Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs.
Fiebig HH; Schüler J; Bausch N; Hofmann M; Metz T; Korrat A
Cancer Genomics Proteomics; 2007; 4(3):197-209. PubMed ID: 17878523
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
6. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
7. Gene expressions associated with chemosensitivity in human hepatoma cells.
Hoshida Y; Moriyama M; Otsuka M; Kato N; Taniguchi H; Shiratori Y; Seki N; Omata M
Hepatogastroenterology; 2007 Mar; 54(74):489-92. PubMed ID: 17523305
[TBL] [Abstract][Full Text] [Related]
8. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays.
Kang HC; Kim IJ; Park JH; Shin Y; Ku JL; Jung MS; Yoo BC; Kim HK; Park JG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):272-84. PubMed ID: 14734480
[TBL] [Abstract][Full Text] [Related]
9. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
10. Gene signature-based prediction of tumor response to cyclophosphamide.
Korrat A; Greiner T; Maurer M; Metz T; Fiebig HH
Cancer Genomics Proteomics; 2007; 4(3):187-95. PubMed ID: 17878522
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
12. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
13. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
Januchowski R; Zawierucha P; Ruciński M; Zabel M
Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
[TBL] [Abstract][Full Text] [Related]
14. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
Işeri OD; Kars MD; Arpaci F; Gündüz U
Cancer Chemother Pharmacol; 2010 Feb; 65(3):447-55. PubMed ID: 19543729
[TBL] [Abstract][Full Text] [Related]
15. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
Liedtke C; Wang J; Tordai A; Symmans WF; Hortobagyi GN; Kiesel L; Hess K; Baggerly KA; Coombes KR; Pusztai L
Breast Cancer Res Treat; 2010 Jun; 121(2):301-9. PubMed ID: 19603265
[TBL] [Abstract][Full Text] [Related]
17. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs.
Quintieri L; Fantin M; Vizler C
Adv Exp Med Biol; 2007; 593():95-104. PubMed ID: 17265720
[TBL] [Abstract][Full Text] [Related]
18. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
Kars MD; Işeri OD; Gündüz U
Eur J Pharmacol; 2011 Apr; 657(1-3):4-9. PubMed ID: 21320484
[TBL] [Abstract][Full Text] [Related]
19. Dynamic alteration of gene expression induced by anticancer-agent exposure in gastric cancer cell lines.
Takahashi T; Saikawa Y; Nakamura R; Kumagai K; Takeuchi H; Kubota T; Kitagawa Y
Oncol Rep; 2009 Feb; 21(2):451-9. PubMed ID: 19148522
[TBL] [Abstract][Full Text] [Related]
20. Utilization of genomic signatures to identify high-efficacy candidate drugs for chemorefractory endometrial cancers.
Kharma B; Baba T; Mandai M; Matsumura N; Murphy SK; Kang HS; Yamanoi K; Hamanishi J; Yamaguchi K; Yoshioka Y; Konishi I
Int J Cancer; 2013 Nov; 133(9):2234-44. PubMed ID: 23595697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
